Aerie Pharmaceuticals Inc
NASDAQ:AERI
Intrinsic Value
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of AERI.
Aerie Pharmaceuticals Inc's market capitalization is 753.2m USD.
AERI stock price is 15.25 USD.
AERI.
AERI. Open DCF Valuation
AERI. Open Relative Valuation
AERI.
AERI has positive Net Debt. This means that the company has more debt (313m USD) than cash and short-term investments (172m USD).
AERI's ROE (Return on Equity) for the past 12 months is very high and is equal to 31%.
AERI's Revenue has grown by an exceptional 105% over the past 12 months.
AERI's ROE (Return on Equity) has significantly increased in the last 3 years from -301% to 31%.
AERI's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -105% to -15%, and is approaching profitability.
AERI's long-term liabilties (540m USD) exceed its long-term assets (376m USD).
AERI's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -15%.
AERI's short-term assets (303m USD) exceed its short-term liabilties (133m USD).
AERI has negative Operating Income for the last twelve months.
AERI has negative Net Income for the last twelve months.
AERI has positive Gross Profit for the last twelve months.
AERI has positive Free Cash Flow for the last twelve months.
AERI has negative three-year average ROE (Return on Equity): -94%. The company is not efficient at transforming stockholders' equity into net income.
AERI has negative three-year average ROIC (Return on Invested Capital): -99%. The company is not efficient at using invested capital to generate operating income.
AERI's D/E (Debt to Equity) is very low and is equal to -1.91.
AERI's Altman Z-Score is very low and is equal to -3.27.
AERI doesn't generate enough operating income (-27m USD) to safely cover interest payments on its debt (5m USD).
Fundamental Analysis
Aerie Pharmaceuticals Inc
Balance Sheet Decomposition
Aerie Pharmaceuticals Inc
| Current Assets | 302.8m |
| Cash & Short-Term Investments | 172.5m |
| Receivables | 73.9m |
| Other Current Assets | 56.5m |
| Non-Current Assets | 72.8m |
| PP&E | 71.1m |
| Other Non-Current Assets | 1.7m |
| Current Liabilities | 133.3m |
| Accounts Payable | 9.1m |
| Accrued Liabilities | 124.3m |
| Non-Current Liabilities | 406.2m |
| Long-Term Debt | 312.6m |
| Other Non-Current Liabilities | 93.7m |
Earnings Waterfall
Aerie Pharmaceuticals Inc
|
Revenue
|
213.9m
USD
|
|
Cost of Revenue
|
-23.5m
USD
|
|
Gross Profit
|
190.4m
USD
|
|
Operating Expenses
|
-217.1m
USD
|
|
Operating Income
|
-26.7m
USD
|
|
Other Expenses
|
-9.8m
USD
|
|
Net Income
|
-36.6m
USD
|
Free Cash Flow Analysis
Aerie Pharmaceuticals Inc
What is Free Cash Flow?
AERI Profitability Score
Profitability Due Diligence
Aerie Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Aerie Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
AERI Solvency Score
Solvency Due Diligence
Aerie Pharmaceuticals Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Aerie Pharmaceuticals Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AERI Price Targets Summary
Aerie Pharmaceuticals Inc
Ownership
AERI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AERI Price
Aerie Pharmaceuticals Inc
| Average Annual Return | -41.37% |
| Standard Deviation of Annual Returns | 4.96% |
| Max Drawdown | -89% |
| Market Capitalization | 753.2m USD |
| Shares Outstanding | 49 417 400 |
| Percentage of Shares Shorted | 3.13% |
Company Profile
Aerie Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. The company is headquartered in Durham, North Carolina and currently employs 376 full-time employees. The company went IPO on 2013-10-25. The firm is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The firm's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.
You don't have any saved screeners yet
